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Multiple Myeloma in a Patient With Familial Mediterranean 
Fever
Bahman Bashardoust,1 Nasrollah Maleki2
Familial Mediterranean fever (FMF) is an autosomal recessive disease 
characterized by recurrent episodes of painful inflammation in the 
abdomen, chest, or joints. The coexistence of multiple myeloma 
(MM) and FMF is an extremely rare event. Here, we report a case 
of FMF with concurrent MM. A 63-year-old woman was diagnosed 
with FMF since 15 years earlier. She was admitted with a complaint 
of low back pain. Regarding the presence of back pain, anemia, 
hypercalcemia, and kidney failure, a diagnosis of MM was suspected. 
A skeletal survey showed punched-out lesions in the skull. Serum 
protein electrophoresis demonstrated an immunoglobulin G kappa 
monoclonal gammopathy, and bone marrow aspiration revealed 
30% involvement by abnormally appearing plasma cells, suggestive 
of MM. Although the association between FMF and MM may be 
a mere coincidence, further studies are necessary to understand 
their concurrent development.
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INTRODUCTION
Familial Mediterranean fever (FMF) is an 
autosomal recessive disease characterized by 
recurrent episodes of painful inflammation in 
the abdomen, chest, or joints.1,2 The FMF gene, 
also named as Mediterranean fever (MEFV) gene, 
is located on the short arm of chromosome 16.3 
Multiple myeloma (MM) is a neoplastic plasma-cell 
disorder that is characterized by clonal proliferation 
of malignant plasma cells in the bone marrow 
microenvironment, monoclonal protein in the 
blood or urine, and associated organ dysfunction.4 
Multiple myeloma in patients with FMF is very rare 
and its association with FMF is very exceptional. 
We report a case of FMF presenting with nephrotic 
syndrome and chronic kidney failure which were 
found to be due to MM.
CASE REPORT
A 63-year-old Iranian woman was diagnosed with 
FMF 15 years earlier. The clinical presentations of 
the FMF were characterized with recurrent short 
episodes of fever and severe abdominal pain 
accompanied by unilateral pleuritis. Although the 
clinical presentations of the patient was suggestive 
of FMF, we performed a molecular analysis of her 
DNA looking for mutations in the MEFV alleles 
and 2 mutations were identified as V726A and 
A744S. Oral administration of colchicine, 1 mg 
daily, was started, and the response was dramatic: 
the febrile attacks disappeared and the patient had 
an increased feeling of well-being and rising levels 
of physical activity for many years.
At the time of FMF diagnosis, laboratory values 
were as follows: serum creatinine, 1.4 mg/dL 
(reference, 0.5 mg/dL to 1.1 mg/dL); blood urea 
nitrogen, 48 mg/dL (reference, 6 mg/dL to 20 
mg/dL); and urine protein excretion in 24-hour 
urine collection, 3800 mg (reference, < 150 mg). 
Amyloidosis was clinically suspected, and an 
abdominal fat-pad biopsy was performed, which 
was positive for Congo red stain for amyloid. 
The patient was treated with colchicine, calcitriol, 
losartan, and captopril. Several months after the 
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start of treatment, kidney function was improved 
and proteinuria declined to less than 500 mg/d. 
The patient was visited at the outpatient clinic 4 
times per year.
Six month prior to the most recent clinic visit, 
the patient was admitted to the neurosurgery 
department with a complaint of severe low back 
pain. Back pain had been intensified with activity 
and prevented the patient from everyday activities. 
However, the diagnosis was severe osteoporosis 
of the lumbar spine, and the patient underwent 
an external fixation of lumbar spine.
Five months after discharge from the neurosurgery 
service, the patient was admitted to our department 
with complaints of peripheral edema and no 
improvement in back pain. On physical examination, 
the patient was hemodynamically stable. There was 
no palpable lymphadenopathy, hepatomegaly, or 
splenomegaly. Her complete blood count showed 
a hemoglobin level of 10.6 g/dL (reference, 12 g/
dL to 16 g/dL), a platelet count of 350 × 109/L 
(reference, 150 × 109/L to 450 × 109/L), and a 
leukocytes count of 8.6 × 109/L (reference, 4.5 × 
109/L to 10 × 109/L). Other laboratory tests on the 
serum showed a urea nitrogen level of 54 mg/dL, 
a creatinine level of 1.7 mg/dL, an albumin level 
of 4.2 g/dL (reference, 3.5 g/dL to 5.5 g/dL), 
an erythrocyte sedimentation rate of 85 mm/h 
(reference, ≤ 29 mm/h), a sodium level of 136 
mEq/L (reference, 135 mEq/L to 145 mEq/L), a 
potassium level of 4.8 mEq/L(reference, 3.5 mEq/L 
to 5.0 mEq/L), and a calcium level of 11.5 mg/dL 
(reference, 8.5 mg/dL to 10.2 mg/dL). The results 
of 24-hour urine collection showed a nephrotic-
range proteinuria (7000 mg/d).
Regarding the presence of back pain, anemia, 
e l eva ted  e ry throcyte  sed imenta t ion  ra te , 
hypercalcemia, and kidney failure, a diagnosis 
of MM was suspected. A skeletal survey showed 
multiple well-defined lytic lesions (punched-out 
lesions) with variable sizes in the skull (Figure 1). 
Serum protein electrophoresis and immunofixation 
electrophoresis were performed that demonstrated 
immunoglobulin G kappa monoclonal gammopathy 
(Figure 2), and bone marrow aspiration and 
biopsy showed 30% involvement by abnormally 
appearing plasma cells with eccentric nuclei and a 
perinuclear halo of clearer cytoplasm, suggestive of 
MM (Figure 3). The patient was then treated with 
chemotherapy (bortezomib, cyclophosphamide, 
and dexamethasone). However, clinical follow-up 
showed no improvement in back pain and kidney 
failure.
DISCUSSION
Although the exact etiologic factors of MM 
are not known or well established, there are 
some factors which may increase the risk of 
developing the disease. An elevated risk of MM 
has been associated with older age, male sex, 
black race, positive family history, radiation, 
immunosuppression, infections, medication use, 
occupational exposures, and lower levels of 
education, income, and socioeconomic status.5 
The role of medication use in MM risk remains 
unclear. However, there is very little information 
on medication use and subsequent risks of MM. 
In a population-based case-control study among 
Figure 1. Multiple well-defined lytic lesions (punched-out 
lesions) with variable sizes in the skull.
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Connecticut women, use of various medications, 
such as insulin, steroidal anti-inflammatory drugs, 
and gout medication have been associated with 
increased risk of MM.6
Colchicine is a neutral and liposoluble alkaloid 
that interferes with microtubule growth and 
mitosis.7 Colchicine blocks mitosis and has been 
associated in rare cases with hematological 
complications and leukemia. Until additional reports 
of drug toxicity become available, patients with 
gout receiving colchicine should undergo careful 
hematological evaluation. Thus, the occurrence of 
MM in patients with gout might be accepted as a 
manifestation of colchicine toxicity.8
There are reports that show a co-occurrence of a 
group of malignancies with FMF, which leads to the 
conclusion that some of the connections between the 
FMF and carcinogenesis have been established.9,10 
It is hypothesized that the MEFV gene is a cancer 
susceptibility gene.11 High frequencies of the MEFV 
gene mutations have been identified in patients 
with myeloid neoplasm.12,13 In patients with the 
MEFV gene, pyrin serves a key role in regulating 
the intensity of the inflammatory response. Pyrin, 
the protein product of the MEFV gene, functions in 
the modulation of interleukin-1β and nuclear factor 
kappa B. Therefore, any variant of the MEFV gene 
prevents the formation of normal pyrin protein, 
Study Year Country Age, y Sex Symptoms of FMF
Genetic 
Study
Symptoms of 
MM
Serum Protein 
Electrophoresis
Esquinas 
Blanco et al15
1992 Spain 55 Male Articular involvement Not reported Asymptomatic IgG kappa 
gammopathy
Salem et al16 2013 Tunisia 53 Male Abdominal pain, Febrile 
paroxysms, Inflammatory 
arthritis
M694V 
mutation
Right gluteal pain 
and swelling
IgA kappa 
gammopathy
Present report 2015 Iran 63 Female Recurrent episodes of 
fever and abdominal pain
V726A/A744S 
mutation
Bone pain IgG kappa 
gammopathy
Demographic and Clinical Data of the Reported Patients With Familial Mediterranean Fever (FMF) and Multiple Myeloma (MM)
Figure 2. Serum protein electrophoresis (SPE) and 
immunofixation electrophoresis were performed that 
demonstrated immunoglobulin G kappa monoclonal 
gammopathy.
Figure 3. Bone marrow aspiration and biopsy showed 30% 
involvement by abnormally appearing plasma cells with eccentric 
nuclei and a perinuclear halo of clearer cytoplasm.
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and it may lead to postponed apoptosis and 
inflammation due to the reduced ability of pyrin 
to control nuclear factor kappa B and interleukin-
1β activation.14
The above data suggest that factors such as older 
age, colchicine, and the MEFV gene may have a role 
in the occurrence of MM in FMF. The combination 
of FMF in MM is reported only twice in the world 
literature.15,16 Demographic and clinical data of the 
presented cases compared to previously reported 
cases are shown in the Table.
Although the association between FMF and 
MM may be a mere coincidence, further studies 
are necessary regarding this matter.
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